Throughout November, PHA will educate people about risk factors and symptoms of PH through its award-winning interactive, online PH Awareness Month calendar.

WASHINGTON (PRWEB)
October 11, 2022

Each November, the Pulmonary Hypertension Association (PHA) launches a national campaign to raise awareness about pulmonary hypertension (PH). This progressive rare disease is defined by high blood pressure in the lungs and can cause right-heart failure and even death.

This year’s theme is “PHacing the Future Day by Day.” Throughout November, PHA will educate people about risk factors and symptoms of PH through its award-winning interactive, online PH Awareness Month calendar. The calendar reveals a new fact or tool daily, along with downloadable resources to raise PH awareness. This year’s theme compliments the theme of PHA’s biennial conference held in June, “PHacing the Future Together.”

PH is a contributing factor to more than 18,000 adult deaths each year in the United States. It can occur among those with left-heart disease; associated conditions such as sleep apnea, chronic obstructive pulmonary disease (COPD) or scleroderma; or from congenital heart disease. It affects people of any age, sex, race, social or ethnic background.

The disease is significantly underdiagnosed and misunderstood, even among health care providers. Symptoms, including shortness of breath, fatigue and chest pain, aren’t specific to PH and can lead to dangerous delays in diagnosis. While PH is incurable, early diagnosis and proper treatment can extend and improve quality of life.

“PHA and the entire pulmonary hypertension community have made great strides over the years in creating awareness of this disease,” said PHA Board of Trustees Chair Tony Lahnston. “We continue that trajectory and face a bright future with improved support, diagnosis and treatment of PH through education, expanded resources and dedicated research. PHA staff and leadership remain committed to PHA’s mission to extend and improve the lives of those affected by PH.”

PHA’s outreach during November includes social media, advocacy and educational components. PHA offers a PH Awareness Month digital toolkit that includes social media profile and cover photos, social media graphics, an email signature and sample social media posts to raise awareness throughout November.

This year’s events include the PHA Live webinar “Focus on PH Research” on Nov. 15 at 2 p.m. EST. Anna Hemnes, M.D., Evan Brittain, M.D., M.Sc., of Vanderbilt University Medical Center, and expert panelists will inform the PH community about the latest advances in PH research and data presented at the PHA 2022 International PH Conference and Scientific Sessions in Atlanta.

PHA will celebrate PHA’s Day of Action on Nov. 17. This year, PH community members are encouraged to sign the American Lung Association’s oxygen reform petition. The petition asks Congress to change their policies to ensure anyone who needs supplemental oxygen has appropriate access. PH patients, caregivers and loved ones can find additional ways to take action, such as sharing their oxygen access experiences, by visiting PHA’s Advocacy Action Center.

As part of PH Awareness Month, PHA will mark Nov. 9 as CTEPH Awareness Day. Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of PH caused by blood clots in the lungs that harden over time and impede blood flow. Up to 5% of people who develop pulmonary embolisms (blood clots in the lungs) may develop CTEPH. Unlike some forms of PH, CTEPH has treatment options that include a potentially curative surgery.

PHA will also celebrate Giving Tuesday on Nov. 29 as part of its PH Awareness Month activities.

More information about PH, the campaign, and how to raise awareness can be found at PHAssociation.org/awarenessmonth.

About the Pulmonary Hypertension Association

Headquartered in Washington D.C., the Pulmonary Hypertension Association (PHA) is the country’s oldest and largest nonprofit patient association dedicated to the pulmonary hypertension (PH) community. Pulmonary hypertension is a rare, chronic and life-threatening disease of the lungs for which no cure currently exists. PHA’s mission is to extend and improve the lives of those affected by PH. To achieve this mission, PHA engages people with PH and their families, caregivers, health care providers, and researchers worldwide who work together to advocate for the PH community, provide support to patients, caregivers and families, offer up-to-date education and information on PH, improve quality patient care, and fund and promote research. For more information, visit PHAssociation.org and connect with PHA on Twitter, Instagram, Facebook and LinkedIn.

Share article on social media or email:

I’m excited to partner with Smile Brands. They share our commitment to delivering high-quality dentistry and creating a culture where employees love coming to work.

IRVINE, Calif. (PRWEB)
October 11, 2022

Smile Brands, one of the nation’s leading dental support organizations (DSO), is pleased to announce its new affiliate partnership with Palm Springs Family and Cosmetic Dentistry in Palm Springs, CA.

Dr. J. Scott Shepherd leads a team of 16 from his growing Palm Springs location. The team’s philosophy is to treat their patients like family. They strive to provide a comfortable, relaxing, and highly professional dental care experience. The team provides general, cosmetic, specialty, and emergency dental services to patients in Palm Springs and the surrounding Coachella Valley area.

“I’m excited to partner with Smile Brands. They share our commitment to delivering high-quality dentistry and creating a culture where employees love coming to work. The resources Smile Brands offers will benefit my team and allow us to expand care within the community,” said Dr. Shepherd.

Smile Brands will provide administrative support and services to the practice including purchasing, payroll, accounting, IT, billing, facilities management, and marketing. The business will continue to operate under the Palm Springs Family and Cosmetic Dentistry name, and the existing staff will remain with the office.

“We couldn’t be more pleased to partner with Palm Springs Family and Cosmetic Dentistry,” said Steve Bilt, Smile Brands co-founder, and CEO. “Dr. Shepherd and his team are a great fit with our culture. We look forward to supporting their practice growth goals and providing added support and resources so they can focus even more of their time on patient care.”

About Smile Brands:

Smile Brands, based in Irvine, California, is one of the largest providers of dental support services in the United States. The company supports nearly 700 affiliated practices, with more than 7,500 dedicated team members across 30 states. Smile Brands supports a portfolio of over 75 brands including well-known regional brands: Bright Now! Dental, Castle Dental, Merit Dental, Midwest Dental, Monarch Dental, and Mondovi Dental. The company provides comprehensive business support services through exclusive long-term agreements with affiliate dental groups, allowing affiliated practices to spend more time caring for patients and less time on the administrative, marketing, and financial aspects of operating a dental office. The organization receives frequent recognition for its award-winning culture and has been recognized as a Best Place to Work by Glassdoor, Comparably, Stevie® Awards, and more. Smile Brands is a portfolio company of Gryphon Investors, a leading middle-market private equity firm based in San Francisco, California. Visit smilebrands.com for more information.

Share article on social media or email:

Spren is a camera-enabled, digital biomarker platform that connects any app to the human body.

“Spren’s breakthrough technology is going to make a positive impact on the health of people across the globe. I’m excited to support this company and its mission,” said Theo Epstein, a three-time World Series-winning baseball executive.

ASHEVILLE, N.C. (PRWEB)
October 11, 2022

Spren, the company behind top-ranked Heart Rate Variability app Elite HRV, has closed $11.3 million in seed funding to bring its camera-enabled, digital biomarker platform out of stealth mode. This revolutionary technology is designed to empower enterprises across multiple industries and sizes to deliver accurate, evidence-based insights on body composition, heart rate variability (HRV), stress, recovery, cardiovascular fitness, and more.

Led by Drive by DraftKings and featuring notable investors such as two-time Superbowl Champion Eli Manning, MLB Executive and General Manager Theo Epstein, Boston Seed Capital, Karlani Capital, Permit Ventures and others, this Seed funding allows Spren to accelerate expansion of its enterprise biomarker platform into the $1.5 trillion global wellness market.

Spren transforms smartphone cameras into real-time biomarker sensors without additional hardware or wearables. With a few snippets of code, Spren’s SDK and API enhances the user experience through biomarker personalization that improves engagement, retention, and paid conversions. Simultaneously, it helps consumers understand their bodies and make well-informed decisions about their fitness, health, and lifestyle routines.

“So many people need help with their health and well-being, but lack of hardware access can create a serious barrier for many,” Spren Founder & CEO Jason Moore said. “By making targeted biomarker insights more accessible, we’ve already seen hundreds of thousands of people improve their mental and physical well-being. We’re thankful for the support of our investors in fueling our continued innovation and enabling us to accelerate partner integrations that will help us serve millions more people.”

The patented technology behind the Spren platform leverages a decade of research into physiology, behavior and health insights — including collaboration with 117 universities and analysis of more than four billion biomarkers across 20 million user sessions, representing people from all over the world with varying health statuses, performance goals, and lifestyles.

“Measuring stress, recovery and body composition with only a smartphone camera is truly transformative, not just for the sports world but for healthcare overall,” said Theo Epstein, a three-time World Series-winning baseball executive. “Spren’s breakthrough technology is going to make a positive impact on the health of people across the globe. I’m excited to support this company and its mission.”

Expanding on the 715,000+ users of the Elite HRV app, Spren is now rolling out its technology to millions of consumers through partners like Fitbod, Marius Pharmaceuticals, FORTË, and Final Surge.

“We live in a world that cares deeply about living our best lives. Access to tools and technology that enhance our understanding of body composition and the complex signals given off by our bodies play a critical role in ensuring our health, well-being and longevity,” said Meredith McPherron, CEO & Managing Partner of Drive by DraftKings. “The Drive team believes the Spren platform will revolutionize the health and fitness monitoring category and has the real capacity to improve the health of our society generally. We are proud to play such a meaningful role in helping accelerate their journey forward.”

For more information about Spren’s biomarker insights platform, please visit spren.com.

About Spren

Spren is a camera-enabled, digital biomarker platform that connects any app to the human body. Using the smartphone as the sensor, Spren’s evidence-based machine learning algorithms deliver actionable biomarker insights such as HRV, body composition, stress, recovery, progress tracking, and more through an easy to integrate SDK and API. Health and wellness companies are integrating Spren to better understand their users’ holistic health, make their apps more personalized and adaptive, demonstrate measurable progress and empower their members to understand their bodies and make well-informed decisions for their well-being.

Share article on social media or email:

WILMINGTON, Del. (PRWEB)
October 11, 2022

DuPont (NYSE:DD) has announced the launch of liveo.dupont.cn, its new DuPont™ Liveo™ Healthcare Solutions regional website serving Greater China. The company actively has expanded its global footprint – with the new website being the latest development – to better serve customers in China and around the world.

The Liveo™ website helps customers find Chinese-language product and application information for the three markets Liveo™ serves:

• Biopharma Processing – enabling cost-effective, safe manufacturing of biologics used in innovative drugs and vaccines with a wide range of Liveo™ pharma tubing and overmolded assemblies
• Pharmaceutical Solutions – enabling safe, effective new therapeutic drug delivery routes with a unique offering in topical and transdermal solutions, as well as gastrointestinal active pharmaceutical ingredients (APIs)
• Medical Devices – enabling safe, convenient, effective diagnostics, monitoring and treatment at the point of care with a broadening range of specialty medical adhesives and elastomers to support the trend for connected devices and wearables.

DuPont also has made other recent investments in the China market. In August, DuPont announced increased production capabilities for its silicone Liveo™ Pharma Tubing by adding manufacturing capacity in eastern China. The manufacturing expansion aims to meet demand for high-purity biopharmaceutical tubing in Greater China.

“DuPont is committed to pursuing investments in healthcare capabilities to meet the needs of our many fast-growing customers, both in China and elsewhere around the world,” said DuPont Healthcare & Specialty Lubricants Global Business Director Eugenio Toccalino. “We hope to enable our customers to grow, innovate and save lives as we continue our long-term commitment to the healthcare industry.”

The new website can be viewed at liveo.dupont.cn. For Liveo™ product and application information in English, visit liveo.dupont.com.

About DuPont™ Liveo™ Healthcare Solutions

DuPont™ Liveo™ is a globally recognized leader in technology for a broad range of innovations in medical devices, biopharmaceutical processing and pharmaceutical solutions. DuPont high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. We help enable smarter healthcare and positive patient outcomes. More information can be found at liveo.dupont.com.

About DuPont Electronics & Industrial

DuPont Electronics & Industrial is a global supplier of new technologies and performance materials serving the semiconductor, circuit board, display, digital and flexographic printing, healthcare, aerospace, industrial, and transportation industries. From advanced technology centers worldwide, teams of talented research scientists and application experts work closely with customers, providing solutions, products and technical service to enable next-generation technologies.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at http://www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

Overview

On November 2, 2021, DuPont announced it has entered definitive agreements to acquire Rogers Corporation (“Rogers”), (the “Intended Rogers Acquisition”). On January 25, 2022, Rogers shareholders approved the transaction. Closing, is expected by the end of the second quarter 2022, subject to regulatory approvals and customary closing conditions.

On February 18, 2022, DuPont announced that it has entered into definitive agreements to divest a majority of its Mobility & Materials segment, excluding certain Advanced Solutions and Performance Resins businesses, to Celanese Corporation (“Celanese”), (the “M&M Divestiture”). Closing is expected around the end of 2022, subject to regulatory approvals and customary closing conditions.

The Company also announced on February 18, 2022 that its Board of Directors has approved the divestiture of the Delrin® acetal homopolymer (H-POM) business. In addition to the entry into definitive agreements, the Company anticipates that the closing of the sale of Delrin® would be subject to regulatory approvals and other customary closing conditions, (the “Delrin® Business Divestiture” and together with the M&M Divestiture, the “M&M Divestitures”).

Cautionary Statement Regarding Forward Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” and similar expressions and variations or negatives of these words.

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond DuPont’s control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the M&M Divestiture to Celanese, including (x) any failure to obtain necessary regulatory approvals, anticipated tax treatment or to satisfy any of the other conditions to the proposed transaction, (y) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies could impact the value, timing or pursuit of the proposed transaction, and (z) risks and costs and pursuit and/or implementation, timing and impacts to business operations of the separation of business lines in scope for the M&M Divestiture to Celanese, (ii) the timing and outcome of the Delrin® Business Divestiture, including entry into definitive agreements, and the risks, costs and ability to realize benefits from the pursuit of the Delrin® Business Divestiture; (iii) ability to achieve anticipated tax treatments in connection with mergers, acquisitions, divestitures and other portfolio changes actions and impact of changes in relevant tax and other laws; (iv) indemnification of certain legacy liabilities; (v) risks and costs related to each of the parties respective performance under and the impact of the arrangement to share future eligible PFAS costs by and between DuPont, Corteva and Chemours; (vi) failure to timely close on anticipated terms (or at all), realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with mergers, acquisitions, divestitures and other portfolio changes including the Intended Rogers Acquisition and the M&M Divestitures; (vii) risks and uncertainties, including increased costs and the ability to obtain raw materials and meet customer needs, related to operational and supply chain impacts or disruptions, which may result from, among other events, the COVID-19 pandemic and actions in response to it, and geo-political and weather related events; (viii) ability to offset increases in cost of inputs, including raw materials, energy and logistics; and (ix) other risks to DuPont’s business, operations; each as further discussed in DuPont’s most recent annual report and subsequent current and periodic reports filed with the U.S. Securities and Exchange Commission. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

10/11/22

For further information, contact:

Fiona Paul Pinter

Global Communications Leader, Healthcare

+41 79 5713084

fiona.paul-pinter@dupont.com

Image:

https://www.dupont.com/content/dam/dupont/amer/us/en/liveo/public/images/articles/16993_News_Release_Image_ss_1930545608.jpg

Proposed caption:

The recently launched liveo.dupont.cn offers Chinese-language product information and resources to customers in Greater China.

“Seek out and surround yourself with a solid support network. Innovation and motivation are keys in the foundation for success, but without those whom you can lean on and encourage you to keep pushing forward, it can be difficult to pass the finish line.” Said Dr Nattis on her secrets for success

HAUPPAUGE, N.Y. (PRWEB)
October 11, 2022

“Ophthalmology Management” announced the winners of its inaugural “40 Under 40” list. This is a list that represents 40 ophthalmologists under the age of 40 who have achieved excellence in their fields. SightMD is proud to announce that two of their physicians are among these standouts. Based on the nominations, SightMD is very excited to announce Alana Nattis, DO, and Eric Rosenberg, DO, as the two winners who are proudly recognized as part of the next generation of ophthalmologists. Candidates from all around the world in every specialty – including the United States, India, Europe, ranging from oculoplastics to retina and cornea – were all included on the list.

Dr. Nattis is a cornea, cataract and refractive surgeon, as well as director of clinical research at SightMD. Additionally, she is an associate professor in ophthalmology and surgery at NYIT-College of Osteopathic Medicine, and also serves as director of corneal transplantation at Good Samaritan Hospital. Dr. Nattis has published more than 15 articles in peer-reviewed journals, written three textbook chapters, and has co-authored a landmark ophthalmology textbook (now in its second edition) which is designed to help guide and teach surgical techniques to residents and fellows. When asked about her secret to success, Dr. Nattis said: “Seek out and surround yourself with a solid support network. Innovation and motivation are keys in the foundation for success, but without those whom you can lean on and encourage you to keep pushing forward, it can be difficult to pass the finish line.” Dr. Nattis continues to be involved in clinical research and regularly makes presentations at national meetings. Her awards include “Super Doctors Rising Stars” (for two years in a row), a “Best in Session” designation from ASCRS, “Ophthalmic World Leader Rising Star” and “Phi Beta Kappa.”

Dr. Rosenberg specializes in complex anterior segment and cornea surgery at SightMD in Babylon, NY. He has been selected to lead panels at major national meetings, has won several “Best Paper” awards at ASCRS, and also heads ground-breaking clinical trials. Dr. Rosenberg is actively involved in teaching residents at both Northwell and New York Medical College, and is the founder of the Digital Ophthalmic Society, which leads the way in how digitization will shape ophthalmology in the future. He has published more than 25 articles, five book chapters, and “Operative Dictations in Ophthalmology”, a textbook used throughout the world. He is passionate about education and the meshing of technology, engineering, and medicine. Dr. Rosenberg was selected as a “Rising Star Super Doctor” by The New York Times in 2021 and 2022.

About “Ophthalmology Management”

Earlier this year, “Ophthalmology Management” asked its readers for nominations for its inaugural “40 Under 40” list. The goal was to highlight the next generation of ophthalmology, which consists of 40 ophthalmologists – under 40 years old – who have achieved excellence in their fields. The response was huge as there were more than 100 nominations that detailed the efforts by many young surgeons in research, innovation, leadership, teaching, entrepreneurship, academics, and global health, among other points. The “Ophthalmology Management” selection committee voted on the nominees and whittled the list down to a final 40.

About SightMD

SightMD is a rapidly-growing integrated ophthalmic provider group that offers patients access to over 80 eye care providers through the convenience of 40 locations across New York. SightMD’s track record of providing clinically-excellent care spans over 50 years, and its services include general eye exams, laser cataract surgery and lens implantation, glaucoma management, retinal disorder treatment, corneal services, neuro-ophthalmology, LASIK laser vision correction, oculoplastic surgery, pediatric ophthalmology, and audiology. Sight Growth Partners is the administrative services provider for SightMD. For more information about SightMD, please visit https://www.sightmd.com/sightmd-ny/

Share article on social media or email:

PHOENIX (PRWEB)
October 11, 2022

Vidium Animal Health announced today that it has partnered with Torigen Pharmaceuticals, an animal health biologics company, to offer genomic testing and precision medicine to more veterinarians. By opening up the use of personalized, precision medicine to the veterinary marketplace, Vidium and Torigen are providing specialists and general practicing veterinarians with more options to advance the care of dogs with cancer.

Vidium’s genomic-based diagnostic products leverage the latest science available to provide critical information about a dog’s cancer. The company’s best-in-class genomic diagnostic test, SearchLight DNAⓇ, uses next-generation sequencing to identify important mutations in 120 relevant cancer genes. Knowing a tumor’s genetic fingerprint can aid in the diagnosis and prognosis of cancer and inform treatment decisions. Vidium also offers a world-renowned specialty pathology team to support the diagnosis and treatment planning of diseases in small and large animals.

Torigen’s expert sales team will now include SearchLight DNA alongside the company’s personalized cancer immunotherapies in its precision medicine portfolio. When current treatment options aren’t right for pets with cancer, Torigen offers a different solution. Using a portion of the patient’s own tumor, Torigen’s lab prepares a personalized vaccine, harnessing the patient’s immune system to fight cancer.

Canine cancer care is becoming more accessible and precise with these diagnostic and therapeutic tools. Together with veterinarians all over the country, Vidium and Torigen are helping expand options for the pets we love.

“By leveraging the sales team at Torigen to provide veterinarians a suite of advanced precision cancer diagnostic tools, we can offer veterinary teams a unique combination of genomic, pathology, and oncology expertise to expand their options and help improve outcomes for their patients,” comments David Haworth, DVM, PhD, President and Co-founder at Vidium.

“We are thrilled to be working with the team at Vidium,” adds Ashley Kalinauskas, founder and CEO of Torigen. “”The combination of the company’s diagnostic tests and precision medicine expertise coupled with our targeted cancer treatment will give veterinarians and their clients more cancer treatment options. I’m excited to leverage our specialty sales force to deliver value to veterinary clinics across the country.”

ABOUT VIDIUM ANIMAL HEALTH:

Vidium Animal Health, a subsidiary of Translational Genomics Research Institute (TGen), is committed to advancing the understanding of disease to give pets the fullest lives possible. The company provides diagnostic tests to veterinary oncologists, general practitioners, and pet parents, and is passionate about unraveling the genetic components of common and complex diseases, including cancer. Vidium was built on a foundation of unimpeachable science and is led by a knowledgeable and experienced team with deep veterinary and clinical genomic roots. For more information, visit: vidiumah.com. Follow Vidium on Facebook, LinkedIn, and Twitter @vidiumah.

ABOUT TGEN, AN AFFILIATE OF CITY OF HOPE:

Based in Phoenix, Arizona, Translational Genomics Research Institute (TGen) is a nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes, and other life-threatening diseases: CityofHope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes, and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through the efficiency and effectiveness of the translational process. For more information, visit: tgen.org. Follow TGen on Facebook, LinkedIn, and Twitter @TGen.

ABOUT TORIGEN PHARMACEUTICALS:

Torigen is an animal health biologics company dedicated to helping pets with cancer and other unmet medical needs in veterinary medicine. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is focused on providing affordable and accessible cancer care solutions for all companion animals. Torigen recognizes the instrumental role pets play in our families and is determined to extend the lives of companion animals despite a cancer diagnosis.

For more information about Torigen, please visit http://www.torigen.com. Follow Torigen on Facebook, LinkedIn, and Instagram.

Share article on social media or email:

More than two years into our partnership with Micromedex, we continue to see the value of DynaMedex and how the combined solution benefits all clinicians across the continuum of care. DynaMedex will continue to serve as a one-stop-shop for clinicians at the point of care.

IPSWICH, Mass. (PRWEB)
October 11, 2022

EBSCO Information Services (EBSCO) and Merative add a new face to their integrated clinical decision support solution. Under a new name, DynaMedex™, formerly DynaMed® and Micromedex® with Watson™, continues to enhance clinical decision support and operations for healthcare providers and health systems.

DynaMedex offers the power of combining two award-winning disease and drug solution suites — DynaMed and Micromedex — into one seamless experience. DynaMed quickly surfaces peer-reviewed clinical content, with recommendations supported by the latest clinical evidence from comprehensive disease topics, health conditions, and abnormal findings to highly focused topics on evaluation, differential diagnosis and management. Micromedex is a leading evidence-based online reference database for medication information. More than 3,300 hospitals and health systems worldwide rely on Micromedex to support decision-making in medication therapy management, toxicology, alternative medicine and patient education.

DynaMed was named 2022 Best in KLAS for Clinical Decision Support for the second consecutive year and is a flagship product of EBSCO’s Clinical Decisions suite, which received Frost & Sullivan’s 2022 North America Product Leadership award.

Since the partnership began in March 2020, DynaMedex has continued to grow and increase its offerings connected to the DynaMedex ecosystem. With the integration of – DynaMed Decisions, a tool designed to drive meaningful patient-clinician interactions, clinicians have easy access to additional resources to streamline their workflow and support shared decision-making. The addition of Isabel, a diagnostic decision support tool available in DynaMed, enables clinicians to experience an improved diagnosis quality, leading to cost-effective patient care.

EBSCO Executive Vice President of Clinical Decisions Betsy Jones says that the solution’s new name is indicative of the company’s intent to move the resource forward as EBSCO Clinical Decisions’ new flagship product. “More than two years into our partnership with Micromedex, we continue to see the value of DynaMedex and how the combined solution benefits all clinicians across the continuum of care. DynaMedex will continue to serve as a one-stop-shop for clinicians at the point of care.”

DynaMed Editor in Chief Peter Oettgen, MD, FACC, FAHA, FACP, says that the breadth and depth of the evidence-based content available in DynaMedex has grown tremendously in the last few years. “With DynaMedex, clinicians have access to the most current drug and disease content, extensive coverage of specialty topics, and recommendations that are based on the latest evidence and clinical practice guidelines, providing decision support when they need it.”

With the leading drug information resources, together with the most current disease and condition topics, across the most specialties and unique tools for differential diagnosis and shared-decision-making, DynaMedex is not just a name change, it is the beginning of a new era in clinical care. For more information on DynaMedex, visit http://www.dynamedex.com.

About EBSCO Information Services

EBSCO Information Services (EBSCO) is the preeminent provider of online research content and search technologies serving academic, school and public libraries; healthcare and medical institutions; corporations; and government agencies around the world. EBSCO’s Clinical Decisions suite of products is designed to improve patient care by providing healthcare professionals with the most current, evidence-based answers to clinical questions as they arise at the point of care. For more information, visit the EBSCO website at: http://www.ebsco.com.

For more information, please contact:

Jessica Holmes

EBSCO Information Services

Communications Director

978-414-0420

jmholmes@ebsco.com

Share article on social media or email:

“Diet ID is on a mission to make diet quality—the single leading predictor of mortality and morbidity in the modern world—a vital sign.”

ST. LOUIS (PRWEB)
October 11, 2022

The American College of Lifestyle Medicine (ACLM) has announced the addition of nutrition measurement, management and behavior change platform Diet ID to its Lifestyle Medicine Corporate Roundtable, a group of thought leaders and industry professionals who explore effective clinical innovations, activate marketing strategies, accelerate reimbursement and policy adoption, and pursue research and demonstrations of lifestyle medicine in practice. ACLM launched its Corporate Roundtable in 2016 and it now includes nearly 50 active member organizations in the lifestyle medicine ecosystem.

Lifestyle medicine is a medical specialty that uses therapeutic lifestyle interventions as a primary modality to treat chronic conditions including, but not limited to, cardiovascular diseases, type 2 diabetes, and obesity. Lifestyle medicine certified clinicians are trained to apply evidence-based, whole-person, prescriptive lifestyle change to treat and, when used intensively, often reverse such conditions. Applying the six pillars of lifestyle medicine—a whole-food, plant-predominant eating pattern, physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connections—also provides effective prevention for these conditions.

Diet ID is a business-to-business, software-as-a-service (SAAS) company that has invented, patented, scientifically validated and widely commercialized a revolutionary advance in dietary assessment employing a visual approach to measuring and optimizing diet quality. Compared to other dietary assessment tools, this personalized, customizable platform saves time, effort and cost while generating a personalized route to wellness in just minutes. The first fundamentally new way to measure dietary intake in half a century, Diet ID is on a mission to make diet quality—the single leading predictor of mortality and morbidity in the modern world—a vital sign.

According to multiple studies, diet is the leading predictor of chronic disease risk – more than genetics, physical activity, or smoking. A critical element in health optimization, managing diet is extremely challenging, as it’s tedious, costly to measure and track, and difficult to personalize. Diet ID’s digital nutrition tools quickly help providers understand their population’s nutrition intake, as well as provide a personalized blueprint for changes to improve and optimize health. In addition, used as a dietary intervention, the platform offers the unique ability to impact downstream cost savings achieved through upstream improvement in diet quality.

Rooted in decades of research and validation, Diet ID offers transparency with the fastest way to measure diet quality, food intake, and estimated nutrient intake. Diet ID allows effortless diet quality assessment with its digital one-minute, validated visual dietary assessment. A clinician can generate results and individual plans in real time. For the patient, the Daily Actions Module swaps out burdensome food logging for joyful social challenges, meeting people wherever they are on their health improvement journeys.

“The advancement of lifestyle as medicine in all of its luminous promise to add years to lives, and life to years, is dependent upon pearls of innovation,” said Diet ID Founder and CEO David L. Katz, MD, MPH, FACPM, FACP, FACLM. “Diet ID is to diet as a vital sign as the blood pressure cuff is to blood pressure and should be applied as such universally. The routine inclusion of dietary assessment, and management, is the next evolutionary advance in the standard of food as medicine in clinical care. ACLM’s Corporate Roundtable provides us all the opportunity to explore our synergies, be more than a sum of parts, and make together a greater difference.”

“Nutrition is the foundation of lifestyle medicine, with the power to prevent, treat, and reverse chronic disease,” said ACLM President Cate Collings, MD, FACC, MS, DipABLM. “Conventional dietary assessments are cumbersome and neither user nor provider friendly. Diet ID makes it possible to more easily standardize and streamline dietary measurement so that providers can spend their time and target the resources to best help patients. We welcome Diet ID to our Corporate Roundtable.”

ABOUT DIET ID— Founded in 2016 and headquartered in in Detroit, MI, with a team around the U.S., Diet ID is focused on making dietary assessment a vital sign. Founded by Dr. David L. Katz, lifestyle medicine and nutrition leader and founder of the Yale-Griffin Prevention Research Center, Diet ID provides a scientifically valid approach to help people improve what and how they eat, one bite at a time. The result is permanent habit change, with a preference for healthful foods. Learn more about Diet ID at dietID.com.

ABOUT ACLM–The American College of Lifestyle Medicine is the nation’s only medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health. ACLM educates, equips, empowers and supports its members through quality, evidence-based education, certification and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management.

Share article on social media or email: